The clinical development of repurposed drugs shares many features with that of new molecular entities. However, clinical trials for repurposed drugs depend heavily on existing knowledge of the medicinal product and the scientific hypotheses underpinning the new indication or indications being pursued.
Using concrete examples, the webinar will explore the particularities of drug repurposing and highlight frequently overlooked aspects of pharmacology, clinical trial design and regulatory strategy that may ultimately limit the positive impact of drug repurposing on patients and society.
This webinar is organised by the BioMedical SIG. Join the BioMedical SIG to stay informed.
A lot of fruitful discussions with experienced peers. Very helpful sessions.
Sara Matt-Leubner
University of Innsbruck, Austria
There was ample opportunity to learn from colleagues through the workshop sessions or more formally through speakers either sharing their years of experience or their state of the art research. Well worth attending.
John Gleeson
University of Limerick, Ireland
Good opportunity to discuss common issues with fellow professionals and to get updates about the community.
Giuseppe Visimberga
Leiden University, Netherlands
International presence is amazing, so many countries, universities... represented here!!
Christian Massus
SATT Aquitaine, France
It is always encouraging to see that other TTOs are encountering the same problems that we do!
Aurore De Boom
Université Libré de Bruxelle, Belgium
Join our newsletter and get the latest news